| Source: |
| Type: |
| Also called CCND1 Gatekeeper of Cell-Cycle Commitment The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression. Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer. Cyclin D1 is often found to be overexpressed in various cancers. Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression. Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer. In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response. |
| 2423- | 2DG, | SRF, | 2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | NA |
| 2655- | AL, | Allicin and Digestive System Cancers: From Chemical Structure to Its Therapeutic Opportunities |
| - | Review, | GC, | NA |
| 276- | ALA, | Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B |
| 1158- | And, | GEM, | Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer |
| 207- | Api, | Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells |
| - | in-vitro, | Pca, | LNCaP |
| 211- | Api, | Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice |
| - | in-vivo, | Pca, | NA |
| 314- | Api, | Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis |
| - | in-vitro, | SCC, | HaCaT | - | in-vitro, | SCC, | SCC25 |
| 2639- | Api, | Plant flavone apigenin: An emerging anticancer agent |
| - | Review, | Var, | NA |
| 3382- | ART/DHA, | Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge? |
| - | Review, | Var, | NA |
| 3391- | ART/DHA, | Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug |
| - | Review, | Var, | NA |
| 2323- | ART/DHA, | Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2 |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 |
| 556- | ART/DHA, | Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing |
| - | Review, | NA, | NA |
| 564- | ART/DHA, | Cisplatin, | Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling |
| - | in-vitro, | NA, | HN30 |
| 1334- | AS, | Astragalus membranaceus: A Review of Its Antitumor Effects on Non-Small Cell Lung Cancer |
| - | Review, | NA, | NA |
| 4809- | ASTX, | Astaxanthin Inhibits Proliferation of Human Gastric Cancer Cell Lines by Interrupting Cell Cycle Progression |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | MKN45 |
| 4820- | ASTX, | Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p |
| - | in-vitro, | NPC, | NA |
| 1520- | Ba, | Baicalein Induces G2/M Cell Cycle Arrest Associated with ROS Generation and CHK2 Activation in Highly Invasive Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | TOV-21G |
| 2626- | Ba, | Molecular targets and therapeutic potential of baicalein: a review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 2289- | Ba, | Rad, | Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A |
| - | in-vitro, | ESCC, | KYSE150 |
| 2290- | Ba, | Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer |
| - | Review, | GI, | NA |
| 2474- | Ba, | Anticancer properties of baicalein: a review |
| - | Review, | Var, | NA | - | in-vitro, | Nor, | BV2 |
| 1379- | BBR, | Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells |
| - | in-vitro, | lymphoma, | NA |
| 2678- | BBR, | Berberine as a Potential Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 2686- | BBR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Nor, | NA |
| 2335- | BBR, | Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 4658- | BBR, | Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 |
| 1285- | BetA, | Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells |
| - | in-vitro, | Var, | NA |
| 2745- | BetA, | Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors |
| - | in-vitro, | CRC, | RKO | - | in-vitro, | CRC, | SW480 | - | in-vivo, | NA, | NA |
| 2733- | BetA, | Betulinic Acid Inhibits Cell Proliferation in Human Oral Squamous Cell Carcinoma via Modulating ROS-Regulated p53 Signaling |
| - | in-vitro, | Oral, | KB | - | in-vivo, | NA, | NA |
| 722- | Bor, | Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms |
| - | in-vitro, | Ovarian, | MDAH-2774 |
| 1169- | Bos, | Boswellic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in Orthotopic Mouse Model By Downregulating Inflammatory, Proliferative, Invasive, and Angiogenic Biomarkers |
| - | in-vivo, | CRC, | NA |
| - | in-vitro, | Pca, | DU145 |
| 1422- | Bos, | Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family |
| - | in-vitro, | CRC, | NA | - | in-vivo, | NA, | NA |
| 1426- | Bos, | CUR, | Chemo, | Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer |
| - | in-vivo, | CRC, | NA | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | RKO | - | in-vitro, | CRC, | SW480 | - | in-vitro, | RCC, | SW-620 | - | in-vitro, | RCC, | HT-29 | - | in-vitro, | CRC, | Caco-2 |
| 1427- | Bos, | Acetyl-keto-β-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LS174T |
| 2767- | Bos, | The potential role of boswellic acids in cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2776- | Bos, | Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities |
| - | Review, | Var, | NA |
| 2775- | Bos, | The journey of boswellic acids from synthesis to pharmacological activities |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 2773- | Bos, | Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer |
| - | Review, | Var, | NA |
| 1230- | CA, | Caff, | Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | Human, | NA, | NA |
| 1652- | CA, | Caffeic Acid and Diseases—Mechanisms of Action |
| - | Review, | Var, | NA |
| - | in-vitro, | Cerv, | SiHa |
| 1260- | CAP, | Capsaicin inhibits in vitro and in vivo angiogenesis |
| - | vitro+vivo, | NA, | NA |
| 1517- | CAP, | Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1) |
| - | in-vitro, | Bladder, | TSGH8301 | - | in-vitro, | CRC, | T24 |
| 1145- | CHr, | Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways |
| - | in-vitro, | Cerv, | HeLa |
| 2782- | CHr, | Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 2784- | CHr, | Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review) |
| - | Review, | Var, | NA |
| 2785- | CHr, | Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin |
| - | Review, | Var, | NA |
| 2786- | CHr, | Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives |
| - | Review, | Var, | NA |
| 2790- | CHr, | Chrysin: Pharmacological and therapeutic properties |
| - | Review, | Var, | NA |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4709- | CUR, | Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways |
| - | Review, | Var, | NA |
| 137- | CUR, | Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling |
| - | in-vitro, | Pca, | DU145 |
| 170- | CUR, | Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis |
| - | vitro+vivo, | Pca, | PC3 |
| 9- | CUR, | Curcumin Suppresses Malignant Glioma Cells Growth and Induces Apoptosis by Inhibition of SHH/GLI1 Signaling Pathway in Vitro and Vivo |
| - | vitro+vivo, | MG, | U87MG | - | vitro+vivo, | MG, | T98G |
| 12- | CUR, | Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells |
| - | in-vitro, | MB, | DAOY |
| 15- | CUR, | UA, | Effects of curcumin and ursolic acid in prostate cancer: A systematic review |
| 165- | CUR, | Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP |
| 126- | CUR, | Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 437- | CUR, | Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids |
| - | vitro+vivo, | CRC, | TCO1 | - | vitro+vivo, | CRC, | TCO2 |
| 470- | CUR, | Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line |
| - | in-vitro, | Ovarian, | SKOV3 |
| 456- | CUR, | Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells |
| - | vitro+vivo, | GC, | SGC-7901 |
| 1183- | DHA, | Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF-7 | - | in-vivo, | BC, | NA |
| 2270- | dietMet, | Methionine-restricted diet inhibits growth of MCF10AT1-derived mammary tumors by increasing cell cycle inhibitors in athymic nude mice |
| - | in-vivo, | Var, | NA |
| 5012- | DSF, | Cu, | Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems |
| 27- | EA, | Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice |
| - | in-vivo, | PC, | NA |
| 1621- | EA, | The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art |
| - | Review, | Var, | NA |
| 1613- | EA, | Ellagitannins in Cancer Chemoprevention and Therapy |
| - | Review, | Var, | NA |
| 1606- | EA, | Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells |
| - | in-vitro, | Colon, | HCT15 |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 3238- | EGCG, | Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications |
| - | Review, | Var, | NA |
| 3228- | EGCG, | Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids |
| 1303- | EGCG, | (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation |
| - | in-vitro, | EC, | NA |
| 1655- | FA, | Ferulic acid inhibiting colon cancer cells at different Duke’s stages |
| - | in-vitro, | Colon, | SW480 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Colon, | HCT116 |
| 1654- | FA, | Molecular mechanism of ferulic acid and its derivatives in tumor progression |
| - | Review, | Var, | NA |
| 2845- | FIS, | Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy |
| - | Review, | Var, | NA |
| 2847- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | in-vitro, | CCA, | NA |
| 2857- | FIS, | A review on the chemotherapeutic potential of fisetin: In vitro evidences |
| - | Review, | Var, | NA |
| 2825- | FIS, | Exploring the molecular targets of dietary flavonoid fisetin in cancer |
| - | Review, | Var, | NA |
| 2827- | FIS, | The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment |
| - | Review, | Var, | NA |
| 2828- | FIS, | Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review |
| - | Review, | Var, | NA |
| 2832- | FIS, | Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2843- | FIS, | Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential |
| - | Review, | Var, | NA |
| 1065- | GA, | Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression |
| - | vitro+vivo, | Pca, | NA |
| 1086- | GA, | Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation |
| - | in-vitro, | AML, | K562 |
| 826- | GAR, | Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo |
| - | vitro+vivo, | HCC, | HepG2 | - | vitro+vivo, | Liver, | HUH7 |
| 798- | GAR, | Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol |
| - | in-vitro, | BC, | MCF-7 |
| 801- | GAR, | Cisplatin, | Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers |
| - | in-vivo, | HNSCC, | NA |
| 802- | GAR, | Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway |
| - | in-vitro, | GC, | HGC27 |
| 803- | GAR, | Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 804- | GAR, | Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest |
| - | in-vitro, | EC, | HEC1B | - | in-vitro, | EC, | ISH |
| 30- | Ger, | A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | AsPC-1 |
| 2438- | Gra, | Emerging therapeutic potential of graviola and its constituents in cancers |
| - | Review, | Var, | NA |
| 1232- | Gra, | Graviola: A Systematic Review on Its Anticancer Properties |
| - | Review, | NA, | NA |
| 108- | GSL, | A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | C3H10T1/2 |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2891- | HNK, | Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs |
| - | Review, | Var, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2875- | HNK, | Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | SCC, | H226 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LoVo | - | in-vivo, | CRC, | HCT116 |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | SUM159 |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | BC, | BT549 |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 1293- | Ins, | Inositol Hexaphosphate Inhibits Growth and Induces G1 Arrest and Apoptotic Death of Androgen-Dependent Human Prostate Carcinoma LNCaP Cells |
| - | vitro+vivo, | Pca, | LNCaP |
| 1167- | IVM, | The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer |
| - | vitro+vivo, | NA, | NA |
| 2351- | lamb, | Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 1040- | LE, | Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8+ T cell infiltration |
| - | in-vivo, | Lung, | H1975 |
| 1171- | LT, | The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma |
| - | in-vitro, | CCA, | NA |
| 2928- | LT, | Luteolin-mediated increase in miR-26a inhibits prostate cancer cell growth and induces cell cycle arrest targeting EZH2 |
| 2914- | LT, | Therapeutic Potential of Luteolin on Cancer |
| - | Review, | Var, | NA |
| 3277- | Lyco, | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
| - | Review, | Var, | NA |
| 3276- | Lyco, | Lycopene modulates cellular proliferation, glycolysis and hepatic ultrastructure during hepatocellular carcinoma |
| - | in-vivo, | HCC, | NA |
| 3275- | Lyco, | Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer |
| - | Review, | Var, | NA |
| 4778- | Lyco, | Lycopene exerts cytotoxic effects by mitochondrial reactive oxygen species–induced apoptosis in glioblastoma multiforme |
| - | in-vitro, | GBM, | GBM8401 |
| 4797- | Lyco, | A mechanistic updated overview on lycopene as potential anticancer agent |
| - | Review, | Var, | NA |
| 4795- | Lyco, | Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer |
| - | Review, | BC, | NA |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4786- | Lyco, | Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SkBr3 |
| 4784- | Lyco, | Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives |
| - | Review, | Diabetic, | NA | - | Review, | CardioV, | NA |
| 4780- | Lyco, | Potential inhibitory effect of lycopene on prostate cancer |
| - | Review, | Pca, | NA |
| 1013- | Lyco, | Lycopene induces apoptosis by inhibiting nuclear translocation of β-catenin in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 4516- | MAG, | Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models |
| - | in-vivo, | NSCLC, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 1182- | MushCha, | Ergosterol peroxide from Chaga mushroom (Inonotus obliquus) exhibits anti-cancer activity by down-regulation of the β-catenin pathway in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | DLD1 |
| 930- | MushShi, | Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation |
| - | in-vitro, | Ovarian, | NA |
| 1141- | Myr, | Myricetin: targeting signaling networks in cancer and its implication in chemotherapy |
| - | Review, | NA, | NA |
| 1805- | NarG, | Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota |
| - | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | NA |
| 1269- | NCL, | Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway |
| - | in-vitro, | Pca, | DU145 |
| 1267- | NCL, | Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression |
| - | in-vitro, | HCC, | NA |
| 1227- | OLST, | Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling |
| - | in-vivo, | CRC, | NA |
| 1664- | PBG, | Anticancer Activity of Propolis and Its Compounds |
| - | Review, | Var, | NA |
| 1672- | PBG, | The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers |
| - | Review, | BC, | NA |
| 1676- | PBG, | Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies |
| - | Review, | Var, | NA |
| 4940- | PEITC, | Phenethyl Isothiocyanate (PEITC) Inhibits the Growth of Human Oral Squamous Carcinoma HSC-3 Cells through G 0/G 1 Phase Arrest and Mitochondria-Mediated Apoptotic Cell Death |
| - | in-vitro, | Oral, | HSC3 |
| 1938- | PL, | Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation |
| - | Study, | PSA, | NA | - | in-vivo, | NA, | NA |
| 2948- | PL, | The promising potential of piperlongumine as an emerging therapeutics for cancer |
| - | Review, | Var, | NA |
| 2946- | PL, | Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent |
| - | Review, | Var, | NA |
| 2940- | PL, | Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Kidney, | 786-O | - | in-vitro, | BC, | SkBr3 |
| 3930- | PTS, | A Review of Pterostilbene Antioxidant Activity and Disease Modification |
| - | Review, | Var, | NA | - | Review, | adrenal, | NA | - | Review, | Stroke, | NA |
| 3353- | QC, | Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells |
| - | in-vitro, | Oral, | KON | - | in-vitro, | Nor, | MRC-5 |
| 3354- | QC, | Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine |
| - | Review, | Var, | NA |
| 3380- | QC, | Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases |
| - | Review, | Var, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3362- | QC, | The effect of quercetin on cervical cancer cells as determined by inducing tumor endoplasmic reticulum stress and apoptosis and its mechanism of action |
| - | in-vitro, | Cerv, | HeLa |
| 3368- | QC, | The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update |
| - | Review, | Var, | NA |
| 76- | QC, | Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy |
| - | in-vitro, | Pca, | PC3 |
| 51- | QC, | Effect of Quercetin on Cell Cycle and Cyclin Expression in Ovarian Carcinoma and Osteosarcoma Cell Lines |
| - | in-vitro, | Ovarian, | SKOV3 |
| 53- | QC, | Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer |
| - | in-vitro, | BC, | NA |
| 100- | QC, | Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 45- | QC, | Quercetin Inhibit Human SW480 Colon Cancer Growth in Association with Inhibition of Cyclin D1 and Survivin Expression through Wnt/β-Catenin Signaling Pathway |
| - | in-vitro, | Colon, | CX-1 | - | in-vitro, | Colon, | SW480 | - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | HCT116 |
| 43- | QC, | Investigation of the anti-cancer effect of quercetin on HepG2 cells in vivo |
| - | in-vivo, | Liver, | HepG3 |
| 40- | QC, | Quercetin arrests G2/M phase and induces caspase-dependent cell death in U937 cells |
| - | in-vitro, | lymphoma, | U937 |
| 86- | QC, | Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3) |
| - | in-vitro, | Pca, | PC3 |
| 91- | QC, | The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells |
| - | in-vitro, | Pca, | PC3 |
| 95- | QC, | Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent |
| - | in-vitro, | Pca, | PC3 |
| 916- | QC, | Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells |
| - | Review, | Ovarian, | NA |
| 923- | QC, | Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health |
| - | Review, | Var, | NA |
| 4827- | QC, | CUR, | Synthetic Pathways and the Therapeutic Potential of Quercetin and Curcumin |
| - | Review, | Var, | NA |
| 993- | RES, | Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | Nor, | HCEC 1CT |
| 881- | RES, | Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | Pca, | DU145 |
| 1489- | RES, | Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer |
| - | Review, | Var, | NA |
| 3063- | RES, | Resveratrol: A Review of Pre-clinical Studies for Human Cancer Prevention |
| - | Review, | Var, | NA |
| 3061- | RES, | The Anticancer Effects of Resveratrol: Modulation of Transcription Factors |
| - | Review, | Var, | NA |
| 2981- | RES, | Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways |
| - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | SW48 |
| 2982- | RES, | The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1 |
| - | in-vitro, | Melanoma, | MSTO-211H |
| 3098- | RES, | Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers |
| - | Review, | Var, | NA |
| 3095- | RES, | Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk |
| - | in-vitro, | BC, | NA |
| 4657- | RES, | Resveratrol, cancer and cancer stem cells: A review on past to future |
| - | Review, | Var, | NA |
| 3029- | RosA, | Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 3003- | RosA, | Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4900- | Sal, | Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications |
| - | Review, | BC, | NA |
| 4903- | Sal, | Salinomycin: A new paradigm in cancer therapy |
| - | Review, | Var, | NA |
| 4905- | Sal, | Salinomycin as a drug for targeting human cancer stem cells |
| - | Review, | Var, | NA |
| 4995- | Sal, | Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 1017- | Sel, | Selenite induces apoptosis in colorectal cancer cells via AKT-mediated inhibition of β-catenin survival axis |
| - | vitro+vivo, | CRC, | NA |
| 1733- | SFN, | Sonic Hedgehog Signaling Inhibition Provides Opportunities for Targeted Therapy by Sulforaphane in Regulating Pancreatic Cancer Stem Cell Self-Renewal |
| - | in-vitro, | PC, | PanCSC | - | in-vitro, | Nor, | HPNE | - | in-vitro, | Nor, | HNPSC |
| 1730- | SFN, | Sulforaphane: An emergent anti-cancer stem cell agent |
| - | Review, | Var, | NA |
| 1726- | SFN, | Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential |
| - | Review, | Var, | NA |
| 1484- | SFN, | Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3301- | SIL, | Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid |
| - | Review, | Var, | NA |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 3290- | SIL, | A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents |
| - | Analysis, | Var, | NA |
| 3323- | SIL, | Anticancer therapeutic potential of silibinin: current trends, scope and relevance |
| - | Review, | Var, | NA |
| 978- | SIL, | A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment |
| - | Review, | NA, | NA |
| 2230- | SK, | Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 2229- | SK, | Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways |
| - | in-vitro, | Melanoma, | A375 |
| 3044- | SK, | Shikonin Inhibits Non-Small-Cell Lung Cancer H1299 Cell Growth through Survivin Signaling Pathway |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 3047- | SK, | Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 2194- | SK, | Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 | - | in-vivo, | NA, | NA |
| 382- | SNP, | Investigation the apoptotic effect of silver nanoparticles (Ag-NPs) on MDA-MB 231 breast cancer epithelial cells via signaling pathways |
| - | in-vitro, | BC, | MDA-MB-231 |
| 358- | SNP, | Preparation of triangular silver nanoparticles and their biological effects in the treatment of ovarian cancer |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 4584- | SNP, | Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 4417- | SNP, | Caffeine-boosted silver nanoparticles target breast cancer cells by triggering oxidative stress, inflammation, and apoptotic pathways |
| - | in-vitro, | BC, | MDA-MB-231 |
| 4409- | SNP, | Plant-based synthesis of gold and silver nanoparticles using Artocarpus heterophyllus aqueous leaf extract and its anticancer activities |
| - | in-vitro, | BC, | MCF-7 |
| 3559- | TQ, | Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3429- | TQ, | Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells |
| - | in-vitro, | AML, | NA | - | in-vivo, | NA, | NA |
| 3427- | TQ, | Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets |
| 3397- | TQ, | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 3422- | TQ, | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
| - | Review, | Var, | NA |
| 3408- | TQ, | Thymoquinone: A small molecule from nature with high therapeutic potential |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3411- | TQ, | Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone |
| - | Review, | Var, | NA |
| 3412- | TQ, | Thymoquinone induces oxidative stress-mediated apoptosis through downregulation of Jak2/STAT3 signaling pathway in human melanoma cells |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vivo, | NA, | NA |
| 3413- | TQ, | Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase |
| - | in-vitro, | CRC, | HCT116 |
| 3414- | TQ, | Thymoquinone induces apoptosis through inhibition of JAK2/STAT3 signaling via production of ROS in human renal cancer Caki cells |
| - | in-vitro, | RCC, | Caki-1 |
| 2124- | TQ, | Thymoquinone: an emerging natural drug with a wide range of medical applications |
| - | Review, | Var, | NA |
| 2120- | TQ, | Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3 |
| - | in-vitro, | Melanoma, | A431 |
| 2097- | TQ, | Crude extract of Nigella sativa inhibits proliferation and induces apoptosis in human cervical carcinoma HeLa cells |
| - | in-vitro, | Cerv, | HeLa |
| 2095- | TQ, | Review on the Potential Therapeutic Roles of Nigella sativa in the Treatment of Patients with Cancer: Involvement of Apoptosis |
| - | Review, | Var, | NA |
| 2108- | TQ, | Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa |
| - | Review, | Var, | NA |
| 2084- | TQ, | Thymoquinone, as an anticancer molecule: from basic research to clinical investigation |
| - | Review, | Var, | NA |
| 2083- | TQ, | Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro |
| - | in-vitro, | GC, | HGC27 | - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 | - | in-vivo, | NA, | NA |
| 2112- | TQ, | Crude flavonoid extract of the medicinal herb Nigella sativa inhibits proliferation and induces apoptosis in breastcancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 4565- | TQ, | Thymoquinone in the clinical treatment of cancer: Fact or fiction? |
| - | Review, | BC, | NA |
| 2411- | UA, | Ursolic acid in health and disease |
| - | Review, | Var, | NA |
| 1020- | UA, | Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/β-Catenin Pathway |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 3132- | VitC, | Vitamin C affects G0/G1 cell cycle and autophagy by downregulating of cyclin D1 in gastric carcinoma cells |
| - | in-vitro, | GC, | MKN45 |
| 2281- | VitK2, | The biological responses of vitamin K2: A comprehensive review |
| - | Review, | Var, | NA |
| 1816- | VitK2, | Role of Vitamin K in Selected Malignant Neoplasms in Women |
| - | Review, | Var, | NA |
| 1817- | VitK2, | Research progress on the anticancer effects of vitamin K2 |
| - | Review, | Var, | NA |
| 1820- | VitK3, | Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:73 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid